MFN is quietly reshaping how you launch globally

Last time I wrote about MFN, it felt like one of those policy shifts that sits in the background. Important, slightly uncomfortable, but still something you could park while you focused on the real work of getting a product to market. That’s no longer the case. MFN has moved from a theoretical pricing debate into something much more tangible, showing up through policy signals, payer behaviour, and increasingly, in the way companies are starting to think about launch.

The mistake I still see is treating MFN as a US pricing issue. On the surface, that makes sense. The policy is US-driven, the rhetoric is about US patients, and the pressure is being applied to US prices. But if you step back and look at how this actually plays out commercially, the impact lands much earlier than that. It lands at the point where you decide how and where your product first enters the global market.

For years, the industry has operated with a relatively stable playbook. You launch where you can get access fastest, often outside the US. You accept that early pricing may not be perfect because it helps build momentum, generate evidence, and demonstrate real-world use. Then, when the US comes online, you optimise properly and capture the bulk of value there. That model only works if markets are loosely connected, if decisions made in one geography don’t materially shape expectations in another.

MFN starts to erode that separation. It doesn’t do it cleanly or consistently, but it doesn’t need to. The mere presence of a policy direction that links US pricing to international benchmarks is enough to change behaviour. Once that expectation exists, even informally, every early pricing decision begins to carry more weight. What used to be a local trade-off becomes something that can echo into your most important market.

That’s where the shift from optimisation to exposure really begins. Early access agreements, managed entry deals, and partner-led negotiations in ex-US markets are no longer just about unlocking uptake in those countries. They become reference points. They create signals about what the therapy is “worth” in practice. And while those signals may not translate directly into US price controls, they shape the environment in which US pricing discussions happen.

This is particularly challenging for companies approaching launch with a single asset or a narrow portfolio. Larger organisations have the ability to absorb variation across markets and products, but smaller companies are far more exposed to the consequences of one or two key decisions. If your commercial future is heavily weighted towards a single launch, the sequencing of that launch becomes critical in a way it hasn’t been before.

The question therefore changes. It is no longer enough to ask where you can launch first or where access will be easiest to secure. The more relevant question is where you can afford to establish your first meaningful price signal. Visibility now comes with consequences. A lower-priced entry in a highly referenced or transparent market can begin to anchor expectations in ways that are difficult to unwind later, even if the original decision made perfect sense locally.

Europe sits right in the middle of this dynamic. It has always been a region where access is prioritised, where pricing negotiations are structured and often conservative, and where early evidence generation is highly valued. In many ways, it provides the foundation for global adoption. But it also tends to set the lower bound of pricing. The US, historically, has set the upper bound. As MFN begins to narrow the gap between those two, the implications ripple through the entire commercial model. Peak revenue assumptions become less certain, partner economics shift, and the margin for error in early pricing decisions becomes much tighter.

There is also a structural challenge in how companies work with partners. Many ex-US licensing agreements were designed around speed and local autonomy. Partners are given flexibility to negotiate within their markets, which makes sense when those decisions are contained within those geographies. Under an MFN-influenced environment, that autonomy carries a different level of risk. A pricing decision taken in one country, without full visibility or control from the originator company, can have unintended consequences beyond that market. What was once a local optimisation becomes a potential global constraint.

All of this brings launch sequencing much closer to the centre of strategy. It is no longer a downstream operational decision about timing and logistics. It is an upstream strategic decision about how value is established and protected. Companies now need to think not just about how quickly they can enter markets, but about the order in which they create price signals, the level of control they maintain over those signals, and how those decisions interact across geographies.

The uncomfortable reality is that this introduces trade-offs that didn’t previously exist in the same way. Speed versus control becomes a more explicit tension. Early access versus long-term price integrity is no longer an abstract consideration. Delaying a launch in a market that is operationally ready may, in some cases, be the more rational decision if it protects value elsewhere. Equally, tightening governance over partner pricing may slow progress but reduce downstream risk.

Ultimately, MFN forces a more integrated view of global commercial strategy. You can no longer treat markets as independent lanes that converge later. The interdependencies are now too strong, or at least too visible, to ignore. The sequencing of your launch, the structure of your deals, and the prices you accept early on are all part of the same system.

The question that sits underneath all of this is relatively simple, but not always comfortable to answer. If your US price ends up being influenced, directly or indirectly, by your lowest meaningful international price, does your asset still deliver the value you expect? If the answer is uncertain, then MFN is not just a policy backdrop. It is something that needs to be actively designed into your strategy.

What this means in practice is that the companies who navigate the next few years successfully will not necessarily be the ones who move fastest. They will be the ones who move with intent. They will understand that early decisions now have amplified consequences and will design their launch approach accordingly. In a world where global pricing signals are increasingly connected, sequencing is no longer just about access. It is about protecting the integrity of the entire commercial opportunity.